Try our Advanced Search for more refined results

Expert Analysis

DEA Hemp Rule Is Safe For Now, But That May Change

By Joshua Mandell, Jonathan Robbins and Courtney Krause (June 15, 2018, 3:16 PM EDT) -- Across the country and throughout the internet, sales of wellness products and alternative medicines containing cannabidiol, known as CBD, are skyrocketing. At the same moment, through an innocuous rule change in late 2016, the U.S. Drug Enforcement Administration announced that CBD, even if extracted from industrial hemp, is classified as a Schedule I drug even though CBD extract is not psychoactive or addictive.[1] Recently, the U.S. Court of Appeals for the Ninth Circuit rejected an industry challenge to the DEA rule....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!